Additionally, since EGF-signaling antagonists are an important clinical tool used in treatment of several types of cancers including colon cancer [44], further studies are needed to determine whether tumors with A20 mutations may be potential targets for EGFR inhibition. This evidence concerns the gene TNFAIP3 and cancer.